Premium
Inhibitory effect of Sihocheonggan‐tang on 2,4‐dinitrochlorobenzene‐induced atopic dermatitis in BALB/c mice
Author(s) -
Chun Jaemoo,
Park Seonghwan,
Jung Jeeyoun
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.09068
Subject(s) - thymic stromal lymphopoietin , atopic dermatitis , immune system , immunoglobulin e , immunology , medicine , balb/c , proinflammatory cytokine , inflammation , antibody
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by complex immune dysregulation. Although the prevalence of AD has increased steadily in recent years, therapeutic treatments remain limited. In this study, we investigated the effects of Sihocheonggan‐tang (SHCG) on AD induced by 2,4‐dinitrochlorobenzene (DNCB) in BALB/c mice. Repeated application of DNCB was performed on the dorsal skin of BALB/c mice, and SHCG was orally administered daily for 2 weeks. We found that SHCG administration alleviated DNCB‐induced AD symptoms such as skin lesion and clinical skin severity score. Histopathological analysis indicated that SHCG significantly reduced the epithelial skin thickness and decreased the expression of thymic stromal lymphopoietin (TSLP), intercellular adhesion molecule‐1 (ICAM‐1), and mast cell infiltration in skin. Also, SHCG administration alleviated the increased immunoglobulin E (IgE) and Th2 cytokines such as IL‐4, TNF‐α, and IL‐6, induced by DNCB in BALB/c mice, suggesting that SHCG suppresses AD via the regulation of Th2 immune responses. Furthermore, we investigated the gut microbiota to clarify the association between AD and composition of gut microbiota. SHCG administration attenuated the abundance of Deferribacteres, which was increased in DNBC‐induced AD mice. Principal coordinate analysis (PCoA) revealed a separation of SHCG group from AD group at the species level. These results suggest that SHCG may be a promising therapeutic candidate for the treatment of AD by modulating gut microbiota composition.